ModeX Starts Dosing in MDX2003 Trial for B-Cell Lymphoma

Why It Matters

The trial could validate a next‑generation T‑cell engager that addresses resistance mechanisms in B‑cell lymphoma, potentially reshaping the therapeutic landscape and expanding OPKO Health’s oncology portfolio.

Key Takeaways

• MDX2003 targets CD19, CD20, CD3, CD28 simultaneously.
• First-in-human trial assesses safety, PK, immune activity.
• Dual antigen targeting aims to prevent tumor escape.
• Dose escalation and expansion phases cover multiple B‑cell lymphoma subtypes.
• ModeX leverages tetraspecific platform for broader oncology pipeline.

Pulse Analysis

B‑cell lymphoma remains a formidable challenge, accounting for roughly 85 % of non‑Hodgkin lymphoma cases, yet 30‑40 % of patients relapse after standard chemo‑immunotherapy. Immuno‑oncology has turned to bispecific T‑cell engagers, but antigen loss and limited T‑cell activation often blunt efficacy. ModeX’s entry into this space with a tetraspecific construct reflects a broader industry shift toward multi‑targeted biologics that aim to outmaneuver tumor heterogeneity while preserving safety.

MDX2003’s design is distinctive: it binds CD19 and CD20 on malignant B cells while simultaneously engaging CD3 and CD28 on T cells. The CD28 co‑stimulatory signal is intended to amplify T‑cell proliferation and cytokine release, potentially delivering a more potent and durable anti‑tumor response than conventional CD3‑only bispecifics. Early pre‑clinical work, showcased at the 2025 ASH meeting and the 2026 ESMO Targeted Anticancer Therapies Congress, demonstrated robust cytotoxicity and balanced cytokine profiles, setting a strong rationale for the current first‑in‑human study.

If the MDX2003‑101 trial confirms safety and signals of activity, ModeX could secure a differentiated asset for OPKO Health, enhancing its valuation and attracting partnership interest. The tetraspecific platform also positions the company to expand into other hematologic and solid‑tumor indications, leveraging the same multi‑antigen strategy. In a market crowded with bispecifics, a successful tetraspecific could shift competitive dynamics, prompting larger biotech firms to explore similar architectures and accelerating innovation across the immunotherapy sector.